[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].

MLA

Lin, Li, et al. “[Evaluation of Bevacizumab Combined with Irinotecan-Based Regimen as the First-Line Treatment for Patients with Metastatic Colorectal Cancer].” Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology], vol. 32, no. 10, Oct. 2010, pp. 786–90. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=21163073&authtype=sso&custid=ns315887.

APA

Lin, L., Xu, J., Wang, Y., Ge, F., Liu, L., Zhao, C., Li, S., Liu, J., & Li, Z. (2010). [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology], 32(10), 786–790.

Chicago

Lin, Li, Jian-ming Xu, Yan Wang, Fei-jiao Ge, Lie-jun Liu, Chuan-hua Zhao, Shan-shan Li, Jian-zhi Liu, and Zhi-qiang Li. 2010. “[Evaluation of Bevacizumab Combined with Irinotecan-Based Regimen as the First-Line Treatment for Patients with Metastatic Colorectal Cancer].” Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 32 (10): 786–90. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=21163073&authtype=sso&custid=ns315887.